Clinical Trials Directory

Trials / Completed

CompletedNCT00032942

Lofexidine for Opiate Withdrawal - 1

A Phase III Placebo-Controlled, Double-Blind Multi-Site Trial of Lofexidine for Opiate Withdrawal

Status
Completed
Phase
Phase 3
Study type
Interventional
Enrollment
66 (planned)
Sponsor
National Institute on Drug Abuse (NIDA) · NIH
Sex
All
Age
18 Years – 99 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study is to evaluate lofexidine for opiate withdrawal.

Detailed description

An 11 day inpatient placebo-controlled, double-blind study of 96 opiate dependent, treatment seeking individuals randomized to 2 medication groups: lofexidine and placebo to be conducted in inpatient units at 3 treatment sites.

Conditions

Interventions

TypeNameDescription
DRUGLofexidine

Timeline

Start date
2001-04-01
Primary completion
2004-10-01
First posted
2002-04-08
Last updated
2017-01-12

Locations

3 sites across 1 country: United States

Source: ClinicalTrials.gov record NCT00032942. Inclusion in this directory is not an endorsement.

Lofexidine for Opiate Withdrawal - 1 (NCT00032942) · Clinical Trials Directory